Cytokines upregulate vascular endothelial growth factor secretion by human airway smooth muscle cells: Role of endogenous prostanoids  by Stocks, Joanne et al.
FEBS 29503 FEBS Letters 579 (2005) 2551–2556Cytokines upregulate vascular endothelial growth factor secretion
by human airway smooth muscle cells: Role of endogenous prostanoids
Joanne Stocks, Dawn Bradbury, Lisa Corbett, Linhua Pang, Alan J. Knox*
Division of Respiratory Medicine, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
Received 26 January 2005; accepted 15 February 2005
Available online 7 April 2005
Edited by Robert BaroukiAbstract Here, we report that vascular endothelial growth fac-
tor (VEGF)-A secretion by human airway smooth muscle cells
was increased by interleukin 1 beta (IL-1b) and transforming
growth factor beta (TGFb). IL-1b and TGFb induced cyclo-
oxygenase (COX)-2 protein and increased prostaglandin E2
(PGE2). Both IL-1b and TGFb increased VEGF-A165 mRNA
and VEGF promoter luciferase construct activity, in addition
VEGF-A protein was inhibited by actinomycin D suggesting
transcriptional regulation. The COX inhibitors indomethacin
and NS398 inhibited IL-1b but not TGFb mediated VEGF-A
production. Furthermore, the eﬀect of the COX inhibitors was
overcome by adding exogenous PGE2. In conclusion, IL-1b in-
creases VEGF-A secretion by COX-2 derived PGE2 production
whereas TGFb uses COX-independent pathways.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cyclo-oxygenase1. Introduction
Angiogenesis is a feature of several inﬂammatory and malig-
nant diseases. Pro-inﬂammatory cytokines contribute by gen-
erating vascular endothelial growth factor (VEGF) and other
pro-angiogenic molecules [1,2]. There are at least ﬁve VEGF
gene products termed A–E. VEGF-A, which has several splice
variants (110, 121, 145, 165, 189, and 206), is particularly
important in angiogenesis.
Cytokines such as interleukin 1 beta (IL-1b) and trans-
forming growth factor beta (TGFb) can increase VEGF re-
lease in some cells [3–6]. These agents can exert their
biological eﬀects partly by autocrine generation of lipid medi-
ators [7,8] particularly prostanoids. Arachidonic acid is con-
verted into prostaglandin (PG) H2, by cyclo-oxygenaseAbbreviations: VEGF, vascular endothelial growth factor; TGFb,
transforming growth factor beta; IL-1b, interleukin 1 beta; PGE2,
prostaglandin E2; COX, cyclo-oxygenase; mRNA, messenger RNA;
RT-PCR, reverse transcriptase polymerase chain reaction; HASM,
human airway smooth muscle; ELISA, enzyme linked immunosorbent
assay; NS-398, N-(2-cyclohexyloxy-4-nitrophenyl)-methanesulfona-
mide; MTT, thiazolyl blue, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide
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COX isoforms exist. COX-1 produces housekeeping prosta-
noids, COX-2 is induced by inﬂammatory cytokines [9] and
COX-3 is a splice variant of COX-1 [10]. COX products reg-
ulate several inﬂammatory and remodelling processes includ-
ing chemokine production [11], apoptosis [12] and matrix
metalloproteinase production [12]. Although, COX products
are involved in angiogenic processes [12] their involvement
in cytokine induced VEGF production has not been clearly
deﬁned.
In addition to their contractile and proliferative proper-
ties, human airway smooth muscle (HASM) cells secrete li-
pid mediators, cytokines and chemokines, growth factors
and matrix degrading metalloproteinases reviewed in [13].
We recently showed that HASM can produce VEGF-A
[14] in response to bradykinin. Here, we determined the role
of autocrine prostanoid secretion in cytokine mediated
VEGF release by HASM cells whose main COX product
is PGE2.2. Materials and methods
2.1. Cell culture
Human tracheas were obtained from ﬁve post-mortem individuals
within 12 h of death. Primary cultures of HASM cells were prepared
from explants [15] and used at passage 5–6. Cells were cultured to con-
ﬂuence in 10% fetal calf serum (Seralab, Crawly Down, Sussex, UK)–
Dulbeccos modiﬁed Eagles medium (Sigma, Poole, Dorset, UK)
in humidiﬁed 5% CO2/95% air at 37 C in 24-well culture plates
and growth-arrested in serum deprived medium for 24 h prior to
experiments.2.2. VEGF-A assay
VEGF165 was measured by enzyme linked immunosorbent assay
(ELISA, R&D Systems, Abingdon, Oxon, UK) [15].2.3. PGE2 assay
PGE2 levels were measured by radioimmunoassay [15].
2.4. Western blot analysis
Western blotting for COX-2 was performed as described [15].
2.5. RNA isolation and reverse transcriptase-polymerase chain reaction
(RT-PCR)
Cells were treated with IL-1b (1 ng/ml) or TGFb (10 ng/ml) and col-
lected at 0, 1, 2, 4, and 8 h. Total RNA was isolated (RNeasy kit, Qia-
gen, West Sussex, UK) and reverse transcriptase polymerase chain
reaction (RT-PCR) performed using primers/methods we have de-
scribed [14]. Densitometry was analysed using a GeneGenius gel doc-
umentation and analysis system (Syngene, Cambridge, UK).blished by Elsevier B.V. All rights reserved.
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The VEGF reporter constructs used in transient transfection con-
tained sequences derived from the human VEGF promoter driving
ﬁreﬂy luciferase. A 2.6-kb (bp 2361 to +298) VEGF promoter frag-
ment was used (provided by D. Mukhopadhyay, Harvard, Boston,
MA) [16]. HASM cells were co-transfected using FuGENE 6 (Roche)
with the vector (pRL-TK, Promega) 0.5 lg/ml DNA for 8 h, then cul-
tured with IL-1b or TGFb for 16 h. Transfection eﬃciency was 30%.
Cells were then collected and lysed. Fireﬂy and Renilla luciferase activ-
ities were measured by luminometer using the dual-luciferase reporter
assay system (Promega).
2.7. Drugs/chemicals
The broad spectrum COX inhibitor indomethacin (Sigma), the selec-
tive COX-2 inhibitor N-(2-cyclohexyloxy-4-nitrophenyl)-methanesul-
fonamide (NS-398), from (Cayman Chemical, Ann Arbor, MI,
USA), actinomycin D, (Sigma) were added 1 h prior to IL-1b or
TGFb. Where drugs were dissolved in organic vehicles (e.g., dimethyl
sulfoxide), controls were treated with vehicles.
2.8. Cell viability
The toxicity of the chemicals and their vehicles was determined by
MTT (thiazolyl blue, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltert-
razolium bromide) assay [14].
2.9. Statistical analysis
Data were expressed as means ± S.E.M. Statistical analysis was per-
formed using ANOVA followed by students unpaired two-tailed t test
as a post hoc test to determine the diﬀerences between means. P < 0.05








































Fig. 1. Concentration response (A) and kinetics (B) of the eﬀect of IL-
1b on VEGF-A release. HASM cells were incubated with 1 ng/ml of
IL-1b in kinetic studies or increasing IL-1b concentrations for 24 h for
the concentration response. Mean ± S.E.M., n = 6 from two experi-
ments, experiments in a further two cell lines showed similar results.
\P < 0.05, \\P < 0.01, \\\P < 0.001 compared to controls by t test after
ANOVA showed signiﬁcant diﬀerence (P < 0.001).3. Results
3.1. IL-1b and TGFb increase VEGF-A protein production
IL-1b (0, 0.001, 0.01, 0.1 and 1.0 ng/ml for 24 h) concentra-
tion-dependently increased VEGF-A, signiﬁcant from 0.1 ng/
ml (P < 0.001) (Fig. 1A). TGFb (0.1, 1, 10, and 20 ng/ml)
caused a concentration related increase signiﬁcant from 1 ng/
ml (P < 0.05) (Fig. 2A). A time-dependent increase in
VEGF-A release occurred after IL-1b signiﬁcant after 2 h
(P < 0.001), maximal at 24 h (P < 0.001) (Fig. 1B) and
with TGFb signiﬁcant from 2 h (P < 0.05), maximal at 24 h
(P < 0.001) (Fig. 2B).3.2. IL-1b and TGFb increase VEGF-A mRNA
VEGF-A165 messenger RNA (mRNA) increased over time
after IL-1b and TGFb treatment (Fig. 3A). Actinomycin D
(5 lg/ml) a transcription inhibitor, markedly reduced IL-1b
and TGFb induced mRNA (Fig. 3B) and VEGF-A protein re-
lease (data not shown) suggesting that regulation was tran-
scriptional. Transcriptional arrest studies with actinomycin D
showed no evidence of mRNA stabilisation (data not shown).
3.3. IL-1b and TGFb act transcriptionally
To conﬁrm that IL-1b and TGFb were acting transcription-




































Fig. 2. Concentration response (A) and kinetics (B) of the eﬀect of
TGFb on VEGF-A release. HASM cells were incubated with
increasing TGFb concentrations for 24 h in concentration response
or 1 ng/ml TGFb in kinetic experiments. Mean ± S.E.M., n = 6 from
two experiments, experiments in a further two cell lines showed similar
results. \P < 0.05, \\P < 0.01, \\\P < 0.001 compared to controls by t
test after ANOVA showed signiﬁcant diﬀerence (P < 0.001).
Fig. 3. (A) VEGF-A165 mRNA after IL-1b or TGFb for 0, 1, 2, 4, 8 and 24 h and corresponding GAPDH mRNA levels. Densitometry showed an
increase in VEGF-A165/GAPDH ratio maximal at 4 h for both IL-1b and TGF b (not shown). Representative of three experiments, experiments in a
further 1–2 cell lines showed similar results. (B) Eﬀect of actinomycin D on VEGF-A mRNA expression. Cells were pretreated with actinomycin D
(5 lg/ml) for 30 min before IL-1b (1 ng/ml) or TGFb (10 ng/ml). (C) IL-1b and TGFb increase VEGF promoter luciferase reporter construct activity.
\P < 0.05 compared to controls. Representative of ﬁve experiments.
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luciferase activity (Fig. 3C).
3.4. COX inhibitors inhibit IL-1b but not TGFb induced
VEGF-A production
VEGF-A release by IL-1b (24 h) was markedly inhibited by
indomethacin (1 lM) (Fig. 4). NS398 (1 lM) had a similar ef-
fect suggesting COX-2 products were involved. The eﬀects of
both COX inhibitors were overcome by adding exogenous
PGE2 (0.01 lM), the concentration released by HASM cells
in response to IL-1b. Both indomethacin (1 lM) and NS398
(1 lM) reduced IL-1b induced PGE2 synthesis (Fig. 5). In con-
trast neither indomethacin (1 lM) nor NS398 (1 lM) had an
eﬀect on TGFb induced VEGF release (24 h) (Fig. 4).
The relative potency of IL-1b and TGFb (1 ng/ml, 24 h) at
inducing COX-2 and releasing PGE2 were compared. PGE2
levels were much greater with IL-1b than TGFb (Fig. 5). Con-sistent with this, IL-1b induced alterations in COX-2 protein
levels were sustained longer than TGFb treated cells.
3.5. Cell viability
Cell viability was consistently >95% (data not shown).4. Discussion
The main ﬁnding here is that endogenous PGE2 is a major
autocrine factor in increasing VEGF-A release in response to
IL-1b but not TGFb in HASM cells. We conﬁrmed the role
of COX-derived PGE2 in IL-1b induced VEGF using broad
spectrum and COX-2 selective COX inhibitors and PGE2 res-
cue experiments. RT-PCR, actinomycin D and studies with a
VEGF reporter construct suggested that both IL-1b and
TGFb were acting transcriptionally.
Fig. 5. (A) 1 ng/ml IL-1b induces COX-2 protein production (35 lg
protein loaded). (B) 1 ng/ml TGFb induces COX-2 protein production
(35 lg protein loaded). (C) 24 h PGE2 release after 1 ng/ml IL1b or
TGFb. N = 12 from three experiments. \\P < 0.01, \\\P < 0.001 by t
test after ANOVA showed signiﬁcant diﬀerence (P < 0.001). (D) Eﬀect
of indomethacin (1 lM) or NS398 (1 lM) on PGE2 production by IL-
1b (1 ng/ml). Mean ± S.E.M., n = 6 from two experiments, experi-

























































































Fig. 4. Eﬀect of COX inhibitors on (A): IL-1b (1 ng/ml) or (B) TGFb
(10 ng/ml) induced VEGF-A generation, PGE2 was used at 0.01 lM in
rescue experiments. Mean ± S.E.M., n = 6 from two experiments,
experiments in a further two cell lines showed similar results. \P < 0.05,
compared with control.
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HASM cells is relevant to the bronchial vascular angiogenic
changes in asthma [17]. Bronchial biopsies in asthma shown in-
creased staining for submucosal VEGF-A [18], VEGF-A is in-
creased in induced sputum in stable asthma [19,20] and in
bronchoalveolar lavage ﬂuid in acute asthma [21]. Further-
more, VEGF-A receptor antagonists inhibited airway inﬂam-
mation and hyperresponsiveness in a murine asthma model
[22]. COX-2 expression is also increased in asthmatic airways
reviewed in [23]. Our studies suggest that stimulation of angio-
genesis via VEGF-A may be an important function of COX-2.
We found that stimulation of HASM cells with IL-1b or
TGFb resulted in a time- and concentration-dependent in-
crease in release of VEGF-A protein. Studies measuring
mRNA showed that both IL-1b and TGFb increased
VEGF-A165 mRNA. We focused on this isoform as it is the
isoform measured in the ELISA assay and is the most biolog-
ically active. Actinomycin D inhibited mRNA induction and
VEGF protein release suggesting that IL-1b and TGFb wereacting transcriptionally. Furthermore, transcriptional arrest
studies showed no alteration in mRNA stability. It has previ-
ously been reported that IL-1b and TGFb can release VEGF
from HASM cells [24] but that study did not study the role
of endogenous prostanoids by using pharmacological inhibi-
tors and did not study whether regulation was transcriptional
or post-transcriptional. As our RT-PCR studies with actino-
mycin D suggested that regulation was transcriptional we went
on to do studies using VEGF promoter luciferase constructs.
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moter luciferase construct indicating that VEGF is regulated
transcriptionally by both of these agents. The fact that the
changes in luciferase activity were modest is consistent with
the fact that primary cells such as HASM cells are diﬃcult
to transfect. Studies in some other cell types have shown that
IL-1b and TGFb can activate VEGF transcriptionally [3,4,6],
although have not probed the role of endogenous prostanoids.
We characterised the role of prostanoids using broad spec-
trum (indomethacin) and COX-2 selective (NS398) inhibitors.
The concentrations chosen inhibit COX-2 derived PGE2 gener-
ation by over 90% [25]. The fact that NS-398 had a similar ef-
fect to indomethacin on IL-1b induced VEGF-A generation
suggests COX-2 involvement. This concentration of NS398
does not inhibit COX-1 mediated PGE2 generation from
unstimulated HASM cells where COX-1 is the only COX iso-
form [25] expressed. The suggestion that endogenous COX
products regulate IL-1b induced VEGF-A release is further
strengthened by our experiments showing that exogenous
PGE2 (the major COX metabolite in these cells) [17] could
overcome the COX inhibitor eﬀects at concentrations compa-
rable to those produced by IL-1b. These studies also exclude
any potential non-COX mediated eﬀect of the COX inhibitors
such as activation of PPARs [26]. Unlike the case with IL-1b,
inhibitor studies suggested that TGFbs eﬀects were COX inde-
pendent. Consistent with this TGFb was a weaker inducer of
PGE2 release than IL-1b, causing only a transient COX-2
induction. One study has reported that IL-1b induced
VEGF-A generation in synovial ﬁbroblasts was COX-2 depen-
dent but did not study the mechanism of regulation [5]. No
previous studies in any cell type have looked at the role of
COX products in TGFbs eﬀects.
In conclusion, VEGF-A production is increased in HASM
cells by IL-1b and TGFb suggesting that cytokine-mediated
paracrine VEGF-A production by HASM cells may contribute
to bronchial vascular remodelling in chronic asthma. The fact
that COX-2 derived PGE2 was an intermediatory in the re-
sponse to IL-1b suggests that COX-2 induction may promote
angiogenesis in asthmatic airways. However, TGFb released
VEGF-A predominantly by prostanoid independent pathways.
Our ﬁndings may be relevant to other chronic inﬂammatory
diseases where angiogenesis contributes to remodelling.
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